首页> 美国卫生研究院文献>BMC Structural Biology >3D QSAR pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum
【2h】

3D QSAR pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum

机译:恶性疟原虫M18天冬氨酰氨肽酶的3D QSAR药效基团和分子对接研究以及新型抑制剂的设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) is only aspartyl aminopeptidase which is found in the genome of P. falciparum and is essential for its survival. The PfM18AAP enzyme performs various functions in the parasite and the erythrocytic host such as hemoglobin digestion, erythrocyte invasion, parasite growth and parasite escape from the host cell. It is a valid target to develop antimalarial drugs. In the present work, we employed 3D QSAR modeling, pharmacophore modeling, and molecular docking to identify novel potent inhibitors that bind with M18AAP of P. falciparum.
机译:背景恶性疟原虫M18天冬氨酰氨肽酶(PfM18AAP)是仅在恶性疟原虫基因组中发现的天冬氨酰氨肽酶,对于其生存至关重要。 PfM18AAP酶在寄生虫和红细胞宿主中执行各种功能,例如血红蛋白消化,红细胞入侵,寄生虫生长和寄生虫从宿主细胞逃逸。开发抗疟药是一个有效的目标。在目前的工作中,我们采用了3D QSAR建模,药效团建模和分子对接技术,以鉴定与恶性疟原虫M18AAP结合的新型有效抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号